Traditional Chinese medicine combined with plasma exchange for the treatment of HDN due to maternal-fetal ABO incompatibility
10.13303/j.cjbt.issn.1004-549x.2021.11.010
- VernacularTitle:中药联合血液净化早期干预治疗母婴血型不合新生儿溶血病
- Author:
Yintu MA
1
;
Li CHEN
2
;
Guicong JIA
2
;
Shuwen DONG
1
;
Yi ZHANG
1
;
Jingyan ZHOU
1
;
Xiaoya YANG
1
;
Lihua LI
2
Author Information
1. Blood Transfusion Department, 980 Hospital of PLA Joint Logistics Support Forces, Shijiazhuang 050082, China
2. Hebei Blood Center
- Publication Type:Journal Article
- Keywords:
pregnant woman;
blood group antibody;
antibody titer;
traditional Chinese medicine;
plasma exchange;
hemolytic disease of the newborn
- From:
Chinese Journal of Blood Transfusion
2021;34(11):1209-1212
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To evaluate the efficacy and safety of early interventions by traditional Chinese medicine oral liquid combined with plasma exchange in the treatment of pregnant women with high titer of ABO/Rh antibodies. 【Methods】 156 pregnant women with serum antibodies presenting high titer (ABO ≥512, Rh ≥ 64) in our hospital from May 2018 to April 2021 were randomly divided into traditional Chinese medicine group(group Ⅰ, n=68), traditional Chinese medicine combined with plasma exchange group(group Ⅱ, n=57) and control group (n=31). The control group were given VC, VEand oxygen uptake. Group Ⅰ were further given oral administration of traditional Chinese medicine liquid on the basis of treatment of the controls. GroupⅡwas further treated with plasma exchange on the basis of group I treatment(for 20 days every month). The biochemistry, serum antibody titer and foetus intrauterine growth were monitored. The the efficacy of treatment, as well as pregnancy and neonatal conditions in the three groups were observed. 【Results】 The decrease time of antibody titer and IgG subtype titer in groupⅠ and Ⅱ, relative to the controls, were significantly better(P<0.05). The effective rate of group Ⅰ(72.59%, 49/68) and group Ⅱ(92.98%, 53 /57) were significantly higher than the controls(18.52%, 5/27, with 4 cases excluded). No HDN occurred in group II, indicating superior treatment outcome to group I and the controls. 【Conclusion】 The oral administration of traditional Chinese medicine liquid combined with plasma exchange, with good therapeutic efficacy and maternal-fetal safety, was effective for the early interventions of ABO/Rh incompatible HDN and worthy of clinical application.
